Aranesp is already approved for use in cancer patients who suffer anemia as a result of their chemotherapy. Amgen wanted to extend this indication to include patients who have anemia from the cancer itself.
Aranesp was already being used off-label for these non-chemotherapy cancer patients. Source here. Another report noted that certain patients in the trial already had "an especially dire prognosis." Source here.